Engaging the Field in Research for New Tools

1
Engaging the Field inResearch for New Tools

• Stop TB Partners Forum
• March 23, 2009
• Rio de Janeiro, Brazil
• Peg Willingham
• Aeras Global TB Vaccine Foundation

2
New Diagnostics, Drugs and Vaccines are in the
Pipeline
2008

2007
2009
2010
2011
2012
2015
2014
2013
2016
Diagnostics
Referral Lab
Peripheral Lab
Point of Care
First NewRegimen
Second New Regimen
Drugs
New booster vaccine
New rBCGvaccine
Vaccines
?
?
3
Aeras Global TB Vaccine Foundation Partnerships
in Clinical Development
Cambodian Health Committee Cambodia
St Johns Research Institute India
KEMRI/CDC Kenya
Manhiça Health Research Center Mozambique
Makerere University Uganda
SATVI/University of Cape Town South Africa
4
Induction of Immunity Prime Boost Infants
BCG or rBCG
IM or as an aerosol
Capsids in bacteria or as an aerosol
24 Weeks
14 Weeks
5
Regimens for Adolescents and Adults Previously
Immunized with BCG
rProtein Adjuvant
rProtein Adjuvant
Viral Vector IM or as Aerosol
Viral Vector IM or as Aerosol
Bacterial Phage Nucleocapsids
Capsids in bacteria or as aerosol
Capsids in bacteria or as aerosol
6
TB Alliance Site Assessments 88 sites assessed
globally Information available on TB Alliance
website
Africa 32 sites Asia 24 sites Europe and
Eastern Europe 12 sites North America 7
sites South America 13 sites
7
TB Alliance Partners and Collaborators
TB Alliance REMoxTB Clinical Sites

• Asan Medical Center (South Korea)
• Aurum HIV Vaccine Research and Treatment Centre
  (South Africa)
• Beijing TB, Thoracic and Tumour Research
  Institute (China)
• Chest Disease Institute, Bangkok (Thailand)
• Helen Joseph Hospital, Johannesburg, (South
  Africa)
• Hospital General de Occidente de la Secretaria de
  Salud del Estado de Jalisco (Mexico)
• Hospital Kuala Lumpur (Malaysia)
• Kenya Medical Research Institute
• Kilimanjaro Christian Medical Center (Tanzania)

• Medical Research Council, Durban (South Africa)
• Mbeya Referral Hospital (Tanzania)
• National Taiwan University Hospital
• Rajavithi Hospital, Bangkok (Thailand)
• Shanghai Pulmonary Hospital (China)
• Samsung Medical Center (South Korea)
• Tianjin TB Control Center (China)
• University of Cape Town Lung Institute (South
  Africa)
• Universidad Peruana Cayetano Heredia, Lima (Peru)
  
• University of Stellenbosch (South Africa)
• University Teaching Hospital (Zambia)
• University of Khon Kaen (Thailand)
• Wanchai Chest Clinic (Hong Kong)

8
FIND Partner sites for TB trialsgt50 trial sites
in 25 countries

• 18 sites in Africa, 19 in Asia, 7 in Americas, 8
  in Europe
• Office in India and Uganda
• MOUs with gt12 MOH NTP
• Strong partnerships with international agencies

9

3 Levels of the Health System for New Diagnostics

Time to response
Reference Level 10
LJ - 40d
MGIT 15d
MTBDR 1d
Phage 2d
Microscopy Level 25
Sensitivity
Smear - 60
LED 10
LAMP25
Xpert 40
Health Post 60
Point of care
Symptoms
AG/AB
Molecular
Enose
10
Working Group on New TB Vaccines
Working Group on New TB Diagnostics
Working Group on New TB Drugs